Tenaya Therapeutics (TNYA) Enterprise Value (2020 - 2026)
Tenaya Therapeutics (TNYA) posted quarterly Enterprise Value of -$80.9 million for Q1 2026, up 8.23% year-over-year from -$74.7 million in Q1 2025, and up 19.54% quarter-over-quarter from -$100.5 million in Q4 2025.
Tenaya Therapeutics (TNYA) Enterprise Value (2020 - 2026) Analysis & Trends
Tenaya Therapeutics' Enterprise Value history runs 7 years deep, the most recent figure standing at -$80.9 million for Q1 2026.
- In Q1 2026, Enterprise Value rose 8.23% year-over-year to -$80.9 million; the TTM figure through Mar 2026 stood at -$80.9 million (up 8.23% YoY), while the FY2025 annual figure was -$100.5 million, down 63.63% from the prior year.
- Enterprise Value for Q1 2026 stood at -$80.9 million, up from -$100.5 million in the prior quarter.
- The five-year high for Enterprise Value was -$56.3 million in Q3 2025, with the low at -$210.5 million in Q1 2022.
- The 5-year median for Enterprise Value is -$104.6 million (2023), against an average of -$117.8 million.
- Peak annual rise in Enterprise Value reached 46.71% in 2022, while the deepest fall reached 63.86% in 2022.
- Tenaya Therapeutics' Enterprise Value stood at -$186.5 million in 2022, then soared by 43.9% to -$104.6 million in 2023, then surged by 41.28% to -$61.4 million in 2024, then slumped by 63.63% to -$100.5 million in 2025, then increased by 19.54% to -$80.9 million in 2026.
- Business Quant data shows TNYA's Enterprise Value at -$80.9 million in Q1 2026, -$100.5 million in Q4 2025, and -$56.3 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Enterprise Value (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | -7.85 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | -7.99 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | -5.18 Bn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | -5.14 Bn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | -5.10 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | -3.31 Bn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | -1.16 Bn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 2.12 Bn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | -18.39 Bn |
| 10 | Tenaya Therapeutics | 150.58 Mn | 150.58 Mn | - | -78.10 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -78.10 Mn |
| Mar 31, 2026 | -80.90 Mn |
| Dec 31, 2025 | -100.55 Mn |
| Sep 30, 2025 | -56.30 Mn |
| Jun 30, 2025 | -80.70 Mn |
| Mar 31, 2025 | -88.16 Mn |
| Dec 31, 2024 | -61.45 Mn |
| Sep 30, 2024 | -79.47 Mn |
| Jun 30, 2024 | -99.30 Mn |
| Mar 31, 2024 | -122.25 Mn |
| Dec 31, 2023 | -104.64 Mn |
| Sep 30, 2023 | -121.75 Mn |
| Jun 30, 2023 | -132.51 Mn |
| Mar 31, 2023 | -147.81 Mn |
| Dec 31, 2022 | -186.53 Mn |
| Sep 30, 2022 | -149.45 Mn |
| Jun 30, 2022 | -180.92 Mn |
| Mar 31, 2022 | -210.45 Mn |
| Dec 31, 2021 | -251.30 Mn |
| Sep 30, 2021 | -280.47 Mn |